$17.7 M

FCSC Mkt cap, 15-Oct-2018
Fibrocell Science Net income (Q2, 2018)-5.8 M
Fibrocell Science EBIT (Q2, 2018)-6.1 M
Fibrocell Science Cash, 30-Jun-201815.4 M

Fibrocell Science Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

200.0k180.0k492.0k355.0k

Revenue growth, %

(10%)173%(28%)

Cost of goods sold

722.0k697.0k

Gross profit

(230.0k)(342.0k)

Gross profit Margin, %

(47%)(96%)

R&D expense

6.5m

General and administrative expense

6.7m

Operating expense total

13.3m

EBIT

(37.4m)(26.5m)(19.0m)

EBIT margin, %

(7603%)(7459%)

Interest expense

228.0k828.0k

Interest income

8.0k

Pre tax profit

(34.5m)(15.3m)(16.2m)

Income tax expense

Net Income

(30.6m)(25.6m)(34.5m)(15.3m)(16.2m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

194.0k137.0k79.0k16.0k87.0k215.0k

Cost of goods sold

1.9m793.0k547.0k512.0k147.0k162.0k204.0k18.0k392.0k287.0k

Gross profit

47.0k(25.0k)(125.0k)(2.0k)(305.0k)(72.0k)

Gross profit Margin, %

24%(18%)(158%)(12%)(351%)(33%)

R&D expense

8.4m7.4m1.6m3.1m

General and administrative expense

2.9m2.8m1.6m3.2m

Operating expense total

11.3m10.3m3.3m6.3m

EBIT

(13.1m)(11.0m)(6.6m)(6.2m)(6.9m)(7.4m)(6.8m)(6.7m)(10.3m)(5.0m)(4.5m)(5.0m)(3.0m)(6.1m)

EBIT margin, %

(3538%)(5372%)(8637%)(41675%)(11861%)(2333%)

Interest expense

46.0k183.0k185.0k190.0k381.0k

Interest income

1.0k1.0k2.0k2.0k1.0k1.0k4.0k4.0k12.0k

Pre tax profit

(12.9m)(14.0m)(2.3m)(6.0m)(8.5m)(6.8m)(1.5m)(1.4m)(8.1m)(2.3m)(5.0m)(14.0m)(2.9m)(5.8m)

Income tax expense

Net Income

(12.9m)(14.0m)(2.3m)(6.0m)(8.5m)(6.8m)(1.5m)(1.4m)(8.1m)(2.3m)(5.0m)(14.0m)(2.9m)(5.8m)

Fibrocell Science Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

60.0m37.5m29.3m17.5m17.4m

Accounts Receivable

Inventories

1.2m1.3m1.2m

Current Assets

61.9m39.3m31.0m18.0m17.9m

PP&E

1.7m1.6m1.6m1.5m

Total Assets

69.0m45.6m36.7m19.6m19.4m

Accounts Payable

3.0m1.1m499.0k440.0k862.0k

Short-term debt

Current Liabilities

3.6m3.5m15.4m3.0m4.4m

Long-term debt

Total Liabilities

11.7m10.4m

Additional Paid-in Capital

167.3m143.1m161.3m170.4m187.8m

Retained Earnings

(102.7m)(112.7m)(147.2m)(162.6m)(178.8m)

Total Equity

64.7m14.2m7.9m9.0m

Financial Leverage

1.1 x2.6 x2.5 x2.2 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

16.9m54.0m49.5m44.2m33.3m26.9m36.9m13.1m8.2m21.3m20.6m15.9m12.2m15.4m

Inventories

574.0k506.0k476.0k610.0k544.0k484.0k566.0k475.0k109.0k

Current Assets

19.2m55.5m50.7m45.3m34.9m28.1m38.0m14.6m8.9m21.7m21.1m16.4m12.7m15.9m

Total Assets

26.3m62.4m57.4m51.9m41.2m34.1m43.9m20.2m10.5m23.2m22.7m18.0m14.1m17.3m

Accounts Payable

1.2m903.0k1.4m1.1m1.9m2.0m2.6m893.0k553.0k361.0k566.0k658.0k508.0k635.0k

Current Liabilities

2.6m2.4m3.2m3.6m6.0m5.2m5.3m3.4m3.1m2.5m3.0m3.4m1.9m2.0m

Total Liabilities

3.3m21.3m18.1m18.3m18.9m17.7m12.6m6.9m4.7m12.2m12.2m21.4m7.9m7.9m

Additional Paid-in Capital

120.0m142.2m142.6m142.9m143.5m144.4m160.8m162.0m162.6m170.1m178.0m178.1m187.9m194.0m

Retained Earnings

(97.1m)(101.1m)(103.3m)(109.3m)(121.2m)(128.0m)(129.5m)(148.7m)(156.8m)(159.1m)(167.6m)(181.6m)(181.7m)(184.6m)

Total Equity

23.0m41.1m39.3m33.5m16.4m31.4m13.3m5.8m11.0m10.5m(3.4m)6.3m9.4m

Financial Leverage

1.1 x1.5 x1.5 x1.5 x2.1 x1.4 x1.5 x1.8 x2.1 x2.2 x-5.2 x2.3 x1.8 x

Fibrocell Science Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(30.6m)(25.6m)(34.5m)(15.3m)(16.2m)

Depreciation and Amortization

863.0k883.0k767.0k564.0k384.0k

Accounts Receivable

54.0k12.0k9.0k12.0k

Inventories

(120.0k)26.0k35.0k126.0k

Accounts Payable

2.0m(1.8m)(114.0k)(139.0k)69.0k

Cash From Operating Activities

(20.1m)(22.3m)(24.1m)(29.4m)(17.0m)

Purchases of PP&E

(360.0k)(242.0k)(271.0k)(253.0k)(433.0k)

Cash From Investing Activities

(360.0k)(242.0k)(245.0k)(252.0k)(433.0k)

Dividends Paid

Cash From Financing Activities

49.1m16.1m17.9m17.4m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(25.0m)(14.0m)(16.3m)(22.3m)(8.5m)(15.3m)(1.5m)(1.4m)(8.1m)(2.3m)(5.0m)(19.0m)(2.9m)(5.8m)

Depreciation and Amortization

693.0k222.0k452.0k673.0k140.0k346.0k91.0k184.0k

Accounts Receivable

23.0k(35.0k)(2.0k)11.0k1.0k2.0k

Inventories

(97.0k)91.0k121.0k(13.0k)27.0k87.0k566.0k475.0k

Accounts Payable

248.0k(2.1m)(1.6m)(1.9m)774.0k833.0k2.6m893.0k553.0k361.0k(55.0k)192.0k23.0k51.0k

Cash From Operating Activities

(16.0m)(6.0m)(10.3m)(15.5m)(4.2m)(10.8m)(4.8m)(9.0m)(4.8m)(7.5m)

Purchases of PP&E

(162.0k)(79.0k)(211.0k)(307.0k)(108.0k)(111.0k)(87.0k)(243.0k)(35.0k)(83.0k)

Cash From Investing Activities

(162.0k)(211.0k)(307.0k)(108.0k)(111.0k)(87.0k)(243.0k)(35.0k)(83.0k)

Cash From Financing Activities

1.7m152.0k253.0k7.9m7.6m(420.0k)5.6m

Fibrocell Science Ratios

USDY, 2018

Financial Leverage

1.8 x
Report incorrect company information